Researchers herein investigated if patients with obsessive-compulsive disorder (OCD) who take serotonin reuptake inhibitors (SRIs) and attain wellness (defined as Yale-Brown Obsessive-Compulsive Scale score ≤14 points) after augmentation with exposure/response prevention (EX/RP) therapy can discontinue their SRI with noninferior outcomes compared with those who continue their SRI therapy.

• A 24-week, double-blind, randomized clinical trial, involving 101 patients with OCD who received SRIs and achieved wellness after EX/RP therapy.

• Participants were randomly assigned to either taper to placebo or to continuation of SRIs.

• At 24 weeks, noninferior outcomes were recorded for patients who tapered to placebo compared with patients who continued SRIs; however, there were higher rates of clinical worsening among patients who tapered to placebo.